RCUS Q4 2018 Earnings — Arcus Biosciences, Inc. Revenue & Financial Results | Market Cap Arena

RCUSArcus Biosciences, Inc.

$2B

Q4 2018 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$2M+25.0% YoY

Gross Profit

$2M100.0% margin

Operating Income

-$13M-863.3% margin

Net Income

-$12M-787.1% margin

EPS (Diluted)

$-0.28

QoQ Revenue Growth

-63.6%

Cash Flow

Operating Cash Flow

-$7M

Free Cash Flow

-$7M

Stock-Based Comp.

$1M

Balance Sheet

Total Assets

$275M

Total Liabilities

$40M

Stockholders' Equity

$235M

Cash & Equivalents

$71M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$2M	$1M	+25.0%
Gross Profit	$2M	$1M	+25.0%
Operating Income	-$13M	-$13M	-1.0%
Net Income	-$12M	-$13M	+6.9%